



## SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF 5, 6-DIHYDRO-3-ARYLNAPHTHO [1,2-b] [1,8] NAPHTHYRIDINE AND THEIR DERIVATIVES

M. RANADHEER KUMAR, E. LAXMINARAYANA<sup>a</sup>, D. RAMESH<sup>b</sup>,  
B. SREENIVASULU<sup>c</sup> and M. THIRUMALA CHARY\*

JNTUH College of Engineering, NACHUPALLY – 505501, Karimnagar (A.P.) INDIA

<sup>a</sup>Sreenidhi Institute of Science and Technology, Ghatkesar, HYDERABAD - 501301 (A.P.) INDIA

<sup>b</sup>University College, Mahatma Gandhi University, NALGONDA - 508 001 (A.P.) INDIA

<sup>c</sup>Centre for Pharmaceutical Sciences, JNT University, HYDERABAD - 500 085 (A.P.) INDIA

### ABSTRACT

2-Aminopyridine-3-carboxaldehyde (**1**) on condensation with 3,4-dihydro-6-methoxynaphthalen-1(2H)-one (**2**) afforded 5,6-dihydro-3-methoxynaphtho[1,2-b][1,8] naphthyridine (**3**) in very good yields. It underwent demethylation with aqueous hydrobromic acid to furnish 5,6-dihydronaphtho[1,2-b][1,8]naphthyridin-3-ol (**4**), followed by treatment with trifluoromethane sulfonic anhydride yielded 5,6-dihydronaphtho[1,2-b][1,8]naphthyridin-3-yl trifluoromethane sulfonate (**5**). The compound (**5**) on further treatment with various aromatic boronic acids gave 5,6-dihydro-3-arylnaphtho[1,2-b][1,8]naphthyridine and their derivative (**6a-f**). The structures of these new compounds were established by spectral data. All the new compounds have been screened for their antimicrobial activity.

**Key words:** Synthesis, 5,6-Dihydro-3-methoxynaphtho[1,2-b][1,8]naphthyridine, 5,6-Dihydronaphtho[1,2-b][1,8]naphthyridin-3-yl trifluoromethane sulfonate, Antifungal activity.

### INTRODUCTION

1,8-Naphthyridines is an important class of pharmaceutically active compounds as they have excellent and diverse biological activities such as diuretic<sup>1</sup>, antimalarial<sup>2</sup>, anti-inflammatory<sup>3</sup>, antihypertensive<sup>4</sup> and antibacterial<sup>5,6</sup>. Nalidixic acid, 1,8-naphthyridine derivative is being used for chronic urinary track infection caused by gram negative bacteria<sup>7</sup>. Another 1,8-naphtheridine derivative, gemifloxacin is also found to be an antibacterial agent<sup>8</sup>. However, it is known that (E) - and (Z)-O-(diethylamino) ethyl oximes of 1,8-

\* Author for correspondence; Ph.: +91 9848511562; E-mail: mtcharya@yahoo.com

naphthyridine series are potential drugs for local anesthesia<sup>9</sup> and 1-(2-fluorobenzyl)-3-(2-tolyl)-1,8-naphthyridin-2(1H)-one is used for the treatment of memory disorders, particularly for Alzheimer's disease<sup>10</sup>.

## EXPERIMENTAL

Melting points were determined on a capillary Buchi melting point apparatus and are uncorrected. The <sup>1</sup>H NMR and <sup>13</sup>C spectra were recorded in the indicated solvent on a Varian 500 MHz and 200 MHz spectrometer with TMS as internal standard. All chemical shifts ( $\delta$ ) are reported in ppm from internal TMS. The mass spectra were measured on a GC/MS-QP1000EX (EI, 70 eV) mass spectrometer. Infrared spectra were recorded in KBr on Shimadzu 470 spectrophotometer. Column chromatography was performed on silica gel (Merck 60-120 mesh). All compounds were recrystallised from ethanol.

A few 1,8-naphthyridine derivatives also react with adenosine receptors of subtypes A<sub>1</sub> and A<sub>2</sub><sup>11</sup>. In continuation of our work on 1,8-naphthyridines, the synthesis of 5,6-dihydro-3-arylnaphtho (1,8) naphthyridines (**6a-f**) and their antimicrobial activity is being reported. The sequential pathway leading to the formation of the title products is shown in **Scheme 1**. The required starting intermediate 5, 6-dihydro-3-methoxy naphtho[1,2-b] [1,8] naphthyridine (**3**) was obtained by the condensation of 2-amino pyridine-3-carboxaldehyde (**1**) with 3,4-dihydro-6-methoxynaphthalen-1(2H)-one (**2**) on refluxing with ethanol in the presence of few drops of aqueous potassium hydroxide. Compound (**3**) in aqueous hydrobromic acid, when heated under reflux, underwent demethylation to furnish 5,6-dihydronaphtho[1,2-b][1,8]naphthyridin-3-ol (**4**) in (91%) yield. Compound (**4**) on further treatment with trifluoromethane sulfonic anhydride (Tf<sub>2</sub>O) in dichloromethane and triethyl amine as a base afforded 5,6-dihydronaphtho[1,2-b][1,8]naphthyridin-3-yl trifluoromethanesulfonate (**5**), which on further treatment with various aromatic boronic acids furnished the 5,6-dihydro-3-phenylnaphtho[1,2-b] [1,8]naphthyridines (**6a-f**) in appreciable yields (78-91%).

These compounds were characterized by their elemental analyses and their spectral data. The IR spectra of the obtained compound (**4**) showed strong absorption band in the 3193 cm<sup>-1</sup> region corresponding to OH functional group. In the <sup>1</sup>H NMR spectra, the signal for two aliphatic CH<sub>2</sub> protons of (**3-6a-f**) ring recorded between 2.91-3.42 ppm and the O-methyl protons of (**3**) appeared as singlet at 3.82 ppm. The <sup>13</sup>C NMR spectra show the expected resonance signals of the different carbons, especially the signal two aliphatic CH<sub>2</sub> protons between 35-56 ppm.

**Preparation of 5, 6-dihydro-3-methoxynaphtho[1,2-b] [1,8] naphthyridine (3)**

To a stirred solution of 8.19  $\mu$  moles of 2-amino-pyridine-3-carboxaldehyde (**1**) in 10  $\mu$ L ethanol, 9.83  $\mu$  moles of 3,4-dihydro-6-methoxynaphthalen-1(2H)-one (**2**) was added. To this reaction mixture, few drops of aqueous potassium hydroxide solution were added and then allowed to reflux for 6 hours. The resulting mixture was poured into ice-cold water, the light yellow crude solid thus obtained was filtered and washed with excess of water and dried and recrystallised from ethyl alcohol affording pure product (**3**) (**Scheme 1**). Yield 92%, mp. 264<sup>o</sup>C, <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) ( $\delta$ /ppm): 2.91-3.19 (4H, m, 2 x -CH<sub>2</sub>), 3.82 (3H, s, -OCH<sub>3</sub>), 6.92-8.98 (7H, m, Ar-H), MS: m/z 262 (M<sup>+</sup>, 100%).

**Preparation of 5,6-dihydronaphtho[1,2-b][1,8]naphthyridin-3-ol (4)**

The solution of 5.84  $\mu$  moles of 5,6-dihydro-3-methoxynaphtho[1,2-b][1,8]naphthyridine (**3**) in 10  $\mu$ L 48% aqueous hydrobromic acid was refluxed for 24 hours. The reaction mixture was cooled to room temperature and poured into 20  $\mu$ L of ice-cold water. The yellow colored solid obtained, was filtered and washed with excess of water and dried and recrystallised from ethyl alcohol furnishing pure product (**4**) (**Scheme 1**). Yield 91%, mp. 267<sup>o</sup>C, <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) ( $\delta$ /ppm): 2.91-3.19 (4H, m, 2 x -CH<sub>2</sub>), 6.92-7.62 (3H, m, Ar-H), 8.19 (1H, s, Ar-OH), 8.32-9.18 (4H, m, Ar-H), MS: m/z 248 (M<sup>+</sup>, 100%).


**Preparation of 5,6-dihydronaphtho[1,2-b][1,8]naphthyridin-3-yl-trifluoro methane sulfonate (5)**

To a solution of 5.40  $\mu$  moles of 5,6-dihydronaphtho[1,2-b][1,8]naphthyridin-3-ol (**4**) in 20  $\mu$  L dry dichloromethane, 10.81  $\mu$  moles of triethylamine and 10.81  $\mu$  moles of trifluoromethanesulfonic anhydride were added dropwise over a period of 10 min at 0<sup>o</sup>C. The resulting solution was stirred for 6 hours at room temperature. The reaction mixture was quenched with 10  $\mu$ L aqueous NH<sub>4</sub>Cl solution; then extracted with ethyl acetate and the organic solvent was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> followed by evaporation of the solvent to dryness in vacuum to afford a solid product. The resulting crude compound was purified by column chromatography by using 60-120 mesh silica gel, eluted with dichloromethane in methanol (9 : 1) to yield compound (**5**) as light yellow solid (**Scheme 1**). Yield 91% mp. 245<sup>o</sup>C, <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) ( $\delta$ /ppm): 3.16-3.36 (4H, m, 2 X -CH<sub>2</sub>), 6.82 -9.25(7H, m, Ar-H), MS: m/z 380 (M<sup>+</sup>, 100%).

**General procedure for the preparation of 5,6-dihydro-3-arylnaphtho[1,2-b] [1,8] naphthyridines and their derivatives (6a-f)**

To a solution of 4.95  $\mu$  moles of compound (**5**) in 10  $\mu$ L dry toluene, 14.85  $\mu$  moles

of aryl boronic acid and 2  $\mu\text{L}$  of 2N aqueous  $\text{Na}_2\text{CO}_3$  solution were added. The resulting solution was purged with argon for 1 hr; then catalytic amount of  $\text{Pd}(\text{PPh}_3)_4$  was added and purged with argon for 1 hr at room temperature. The resulting suspension was allowed to reflux for 16 hrs. Then the solvent was removed under reduced pressure and crude was dissolved in 20  $\mu\text{L}$  ethyl acetate and washed with water twice. The organic solvent was dried over anhydrous  $\text{Na}_2\text{SO}_4$  followed by evaporation of the solvent to dryness in vacuum to afford a solid product. The resulting crude compound was purified by column chromatography by using 60-120 mesh silica gel, eluted with dichloromethane in methanol (9 : 1) and further recrystallisation by ethanol yielded compound (6a). Several title compounds were synthesized using different aryl boronic acid in the presence of Pd (0) to yield compound (6a-f). The chemical and spectral data of the compounds (6a-f) are given in Tables 1 and 2.




**Scheme 1: Synthesis of 5,6-dihydro-3-arylnaphtho [1,2-b] [1,8] naphthyridines and their derivatives (6a-f)**

**Table 1: Chemical data of compounds (6a-f)**

Comp.	Ar	m.p (°C)	Yield (%)
<b>6a</b>	C <sub>6</sub> H <sub>5</sub>	267	91
<b>6b</b>	C <sub>6</sub> H <sub>4</sub> F	247	91
<b>6c</b>	C <sub>7</sub> H <sub>4</sub> N	266	78
<b>6d</b>	C <sub>7</sub> H <sub>7</sub> O	268	82
<b>6e</b>	C <sub>5</sub> H <sub>4</sub> N	238	81
<b>6f</b>	C <sub>5</sub> H <sub>4</sub> N	242	80

Elemental analyses for C, H, N are within  $\pm 0.3\%$  of the theoretical values

\*Solvent for crystallization: Ethyl alcohol for (6a-f)

**Table 2: Spectral data of the compounds (6a-f)**

Compd.	<sup>1</sup> H NMR (DMSO-d <sub>6</sub> , ppm)
<b>6a</b>	3.19-3.42 (4H, m, 2 x CH <sub>2</sub> ), 6.91-7.58 (8H, m, Ar-H), 8.21 (1H, s, Ar-H), 8.31-8.43 (2H, t, Ar-H) 8.95-9.04 ((1H, d, Ar-H)
<b>6b</b>	3.19-3.42 (4H, m, 2 x CH <sub>2</sub> ), 7.02-8.18 (7H, m, Ar-H), 8.23-8.27 (2H, dd, Ar-H), 9.15-9.20 (2H, dd, Ar-H)
<b>6c</b>	3.29-3.42 (4H, m, 2 x CH <sub>2</sub> ), 7.12-8.28 (7H, m, Ar-H), 8.25-8.29 (2H, dd, Ar-H), 9.14-9.19 (2H, dd, Ar-H)
<b>6d</b>	3.29-3.42 (4H, m, 2 x CH <sub>2</sub> ), 3.82 (3H, s, OCH <sub>3</sub> ), 7.12-8.28 (7H, m, Ar-H), 8.25- 8.29 (2H, dd, Ar-H), 9.14-9.19 (2H, dd, Ar-H)

Cont...

Compd.	<sup>1</sup> H NMR (DMSO-d <sub>6</sub> , ppm)
<b>6e</b>	3.29-3.42 (4H, m, 2 x CH <sub>2</sub> ), 7.12-8.28 (7H, m, Ar-H), 8.25-8.29 (2H, dd, Ar-H), 9.14-9.19 (2H, dd, Ar-H)
<b>6f</b>	3.29-3.42 (4H, m, 2 x CH <sub>2</sub> ), 7.04-8.19 (7H, m, Ar-H), 8.23-8.32 (2H, dd, Ar-H), 9.18-9.22 (2H, dd, Ar-H)

s, singlet; d, doublet ; dd, doublet of doublets; m, multiplet

## RESULTS AND DISCUSSION

The antimicrobial activity was observed by adopting the glass slide humid chamber technology<sup>12</sup>. The compounds were screened *in vitro* for their antifungal activity against *Alternaria alternate*, *Fusarium oxysporum* and *Curvularia lunata* using griseofulvin as standard for comparison. Compounds (**5**) and (**6b**) showed promising activity against all the three organisms used. Compounds (**6c**), (**6e**) and (**6f**) were active against *Fusarium oxysporum* and *Curvularia lunata*. Compound (**6a**) was active against *Alternaria alternate*. Compounds (**3**), (**4**) and (**6d**) exhibited feeble activity. None of the compounds were found to exhibit significant antibacterial activity against *Bacillus subtilis*, *Streptococcus fecalis* and *Psuedomonas aeruginosa*.

## ACKNOWLEDGEMENTS

The Authors are thankful to the Vice-Chancellor, JNTU, Hyderabad and Principal, JNTUH College of Engineering, Nachupally for providing necessary laboratory facilities and also thankful to the Director, IICT, Hyderabad for recording <sup>1</sup>H NMR and Mass spectra.

## REFERENCES

1. D. K. J. Gorecki and E. M. Hawes, J. Med. Chem., **20**, 124 (1977).
2. G. B. Balin and W. L. Tan, Aust. J. Chem., **37**, 1065 (1984).
3. T. Kuroda, F. Suzuki, T. Tamura, K. Ohmori and H. Hosie, J. Med. Chem., **35**, 1130 (1992).
4. M. Ferrarini, M. Clendio, U. Calderone and G. Lovella, Eur. J. Med. Chem., **33**, 383 (1998).
5. J. Tani, Y. Mushika and T. Yamaguchi, Chem. Pharm. Bull., **30**, 3517 (1982).

6. C. S. Cooper, P. L. Klock, D. T. W. Chu, D. J. Hardy, R. N. Swanson and J. J. Pattner, *J. Med. Chem.*, **35**, 1392 (1992).
7. W. W. Paudler and T. J. Kress, *Advances in Heterocyclic Chem.*, **11**, 124 (1970).
8. N. Suzuki and R. Dohmori, *Chem. Pharma. Bull.*, **27**, 410 (1979).
9. N. Suzuki, *Chem. Pharma. Bull.*, **28**, 761 (1980).
10. N. Suzuki and R. Dohmori, *Chem. Pharma., Bull.*, **27**, 410 (1979).
11. M. Thirumala Chary, K. Mogilaiah and B. Sreenivasulu, *J. Indian. Chem. Soc.*, **64**, 488 (1987).
12. H. W. Seely and P. J. Vandemark, *Microbes in Action*, W.H. San Francisco (1972) p. 163.

*Revised : 30.04.2010*

*Accepted : 02.05.2010*